Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates

Background and Objectives With the implementation of universal white blood cell (WBC) reduction in the UK, in‐process WBC‐reduction filters for pooled buffy coat (BC)‐derived platelet concentrates (PCs) and apheresis methods are used routinely for the production of WBC‐reduced PCs. While these strategies meet the specification for WBC reduction (< 5 × 106 WBCs/unit), the products from these processes may differ depending on the process employed and its performance. The aim of this study was therefore to investigate whether PCs prepared using various WBC‐reduction processes are sufficiently depleted of WBCs to limit cytokine accumulation during storage and to assess if cytokine levels detected in platelet products can serve as indicators of acceptable platelet activation as a result of the WBC‐reduction process.

[1]  L. Williamson,et al.  Platelet storage lesion of WBC‐reduced, pooled, buffy coat‐derived platelet concentrates prepared in three in‐process filter/storage bag combinations , 2001, Transfusion.

[2]  M. Baggiolini,et al.  Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. , 2000, Blood.

[3]  M. Wadhwa,et al.  Cytokines in WBC‐reduced apheresis PCs during storage: a comparison of two WBC‐reduction methods , 2000, Transfusion.

[4]  A. Donnenberg,et al.  WBC subset analysis of WBC‐reduced platelet components , 2000, Transfusion.

[5]  J. Corral,et al.  Evaluation of Leukocyte‐Depleted Platelet Concentrates Obtained by In‐Line Filtration , 2000, Vox sanguinis.

[6]  K. Gutensohn,et al.  Extracorporeal Plateletpheresis Induces the Interaction of Activated Platelets with White Blood Cells , 2000, Vox Sanguinis.

[7]  T. Lyberg,et al.  Apheresis‐induced platelet activation:comparison of three types of cell separators , 2000, Transfusion.

[8]  H. Kirchner,et al.  Febrile and allergic transfusion reactions after the transfusion of white cell‐poor platelet preparations , 1999, Transfusion.

[9]  M. Fujihara,et al.  Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor‐β1 in apheresis platelet concentrates during storage , 1999, Transfusion.

[10]  S. Holme,et al.  Improved removal of white cells with minimal platelet loss by filtration of apheresis platelets during collection , 1999, Transfusion.

[11]  A. Giulivi,et al.  Prevention of Cytokine Accumulation in Platelets Obtained with the COBE Spectra Apheresis System , 1998, Vox Sanguinis.

[12]  S. Sowemimo-Coker,et al.  White cell subsets in apheresis and filtered platelet concentrates , 1998, Transfusion.

[13]  D. Kunz,et al.  Transforming growth factor beta is increased in plasma of patients with hematologic malignancies after transfusion of platelet concentrates , 1998, Transfusion.

[14]  W. Ouwehand,et al.  Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods , 1997, British journal of haematology.

[15]  J. Amiral,et al.  Annexin V, a new marker of platelet storage lesion: correlation with dMPV. , 1997, Transfusion science.

[16]  K. Tadokoro,et al.  Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell‐removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets , 1997, Transfusion.

[17]  J. Beaumont,et al.  A multicenter evaluation of the routine use of a new white cell‐ reduction apheresis system for collection of platelets , 1997, Transfusion.

[18]  S. Holme,et al.  The expression of p‐selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability , 1997, Transfusion.

[19]  M. Peetermans,et al.  Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet‐rich plasma method , 1996, Transfusion.

[20]  H. Kirchner,et al.  Chemokines in stored platelet concentrates , 1996, Transfusion.

[21]  M. Wadhwa,et al.  Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays , 1996, British journal of haematology.

[22]  M. Urashima,et al.  Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage , 1996, Transfusion.

[23]  M. Sticherling,et al.  Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. , 1995, International archives of allergy and immunology.

[24]  H. Kirchner,et al.  Cytokines in Platelet Concentrates Prepared from Pooled Buffy Coats , 1995, Vox sanguinis.

[25]  R. Holcombe,et al.  Quantitation of CD62, soluble CD62, and lysosome‐associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates , 1995, Transfusion.

[26]  A. Giulivi,et al.  Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage , 1995, Transfusion.

[27]  S. Wahl,et al.  Transforming growth factor β: a matter of life and death , 1994 .

[28]  E. Snyder,et al.  Cytokine generation in stored platelet concentrates , 1994, Transfusion.

[29]  T. Wun,et al.  Removal by white cell‐reduction filters of activated platelets expressing CD62 , 1993, Transfusion.

[30]  C. Chitnis,et al.  A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. , 1993, Science.

[31]  T. Schall,et al.  Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. , 1993, The Journal of biological chemistry.

[32]  M. Peetermans,et al.  Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL‐6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL‐6 levels and febrile transfusion reactions , 1993, Transfusion.

[33]  M. Peetermans,et al.  Reactions to platelet transfusion: the effect of the storage time of the concentrate , 1992, Transfusion medicine.

[34]  M. Blombäck,et al.  Proteolytic activity during storage of platelets in plasma , 1992, Transfusion medicine.

[35]  S. Wahl.  Transforming growth factor beta (TGF-β) in inflammation: A cause and a cure , 1992, Journal of Clinical Immunology.

[36]  A. J. Valente,et al.  Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. , 1991, The Journal of clinical investigation.

[37]  R. Hillman,et al.  Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion , 1991, Transfusion.

[38]  P. Rebulla,et al.  Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIb‐IIIa Expression after Filtration through Three Different Leukocyte Removal Filters , 1990, Vox sanguinis.

[39]  M. Sporn,et al.  Deactivation of macrophages by transforming growth factor-β , 1988, Nature.

[40]  R. G. Gaines Das,et al.  SCAN, an exploratory program for preliminary analysis of bioassay and immunoassay data. , 1985, Computer methods and programs in biomedicine.

[41]  A. Lentsch,et al.  Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). , 2000, Blood.

[42]  T. Stokke,et al.  Transforming growth factor-beta potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. , 1995, Blood.

[43]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[44]  S. Wahl,et al.  TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes. , 1990, Growth factors.

[45]  J. Fortynova,et al.  [Platelet concentrates]. , 1988, Casopis lekaru ceskych.